Advanced Pipeline, Aggressive Timeline

At Anji, we focus on high-value, innovative projects that have been credentialed by human data. With a lean operational model that avoids bureaucracy and red tape, we can pursue the best ideas at the right time and work quickly and efficiently to help patients across the globe.

We Focus on What Works

Our custom-built portfolio prioritizes unmet need, without limitations on disease area or therapeutic modality.

Metabolic Disease Pipeline

Molecule

ANJ900 MetDR

Pre-clinical

Phase 1

Phase 2

Phase 3

ANJ908 Pradigastat

ANJ028 ApoE Mimetic

Oncology Pipeline

Molecule

ANJ810 MCL 1 inhibitor

Pre-clinical

Phase 1

Phase 2

Phase 3

ANJ114 HCK Inhibitor

Anji’s oncology programs are being developed by its subsidiary, Anji Onco, Inc.

What’s Happening at Anji

Anji Pharma Secures $70 Million to Deploy Dynamic Equity and Further Build a Global Medicines Company

Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials

Anji Pharma Launches Phase 3 Trial for ANJ900 to Treat Type 2 Diabetes Patients with Kidney Disease

For partnerships, investment opportunities, or to learn more about our work, contact us.